NCT02181946已完成4 期
An Open-label Study in HIV+ Patients to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Fluconazole (DIFLUCAN®)
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- Maximum concentration of the analyte in plasma (Cmax)
研究概览
简要总结
The purpose of this study was to determine the effects of nevirapine on the steady state pharmacokinetics of fluconazole and to assess the steady-state pharmacokinetics of nevirapine when given in combination with fluconazole.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients between the ages of 18 and 65 years who are seropositive for HIV-1 antibody by an ELISA test and confirmed by an alternative method, e.g. Western Blot
- •CD4 + cell count ≥ 100 cells/mm3
- •Patients who meet the following laboratory parameters
- •Granulocyte count > 1000 cells/mm3
- •Hemoglobin > 9.0 g/dl (men and women)
- •Platelet count > 75,000 cells/mm3
- •Alkaline phosphatase < 3.0 times the upper limit of normal
- •Aspartame Transaminase (AST) and Alanine Transaminase (ALT) < 3.0 times the upper limit of normal
- •Total bilirubin < 1.5 times the upper limit of normal
- •Female patients of childbearing potential must be willing to use a reliable form of contraception which must include a medically approved from of barrier contraception
- •Patients able to provide written informed consent and comply with study requirements
排除标准
- •Female patients who are pregnant or breast-feeding
- •Seated systolic blood pressure below 100 mmHg, or greater than 160 mmHg, and/or heart rate less than 50 or greater than 100 beats/min
- •History of drug allergy or known drug hypersensitivity
- •Patients receiving any investigational drug, antineoplastic agent or radiotherapy other than local skin radiotherapy treatment within 12 weeks before starting study medication
- •Patients requiring systemic treatment with corticosteroids or drugs known to be hepatic enzyme inducers or inhibitors within 28 days of study entry (Study Day 1). Such substances in these categories include: macrolide antibiotics (e.g. erythromycin, clarithromycin, azithromycin, dirithromycin), azole antifungals (e.g. itraconazole), rifabutin and phenytoin
- •Patients requiring systemic treatment with CYP3A4 (cytochrome P450 3A4) substrates such as terfenadine, astemizole, cisapride, triazolam and midazolam during the course of the trial
- •Use of protease inhibitors or non-nucleoside reverse transcriptase inhibitors within 28 days of Study Day 1 or during the trial
- •Patients with a current history of intravenous drug abuse, alcohol or substance abuse (within the last year)
- •History of any clinically important disease including hepatic, renal, cardiovascular or gastrointestinal disease
- •Patients with malabsorption, severe chronic diarrhea or patients unable to maintain adequate oral intake
研究组 & 干预措施
Fluconazole with and without Nevirapine
Experimental
干预措施: Fluconazole (Drug)
Fluconazole with and without Nevirapine
Experimental
干预措施: Nevirapine (Drug)
结局指标
主要结局
Maximum concentration of the analyte in plasma (Cmax)
时间窗: up to day 40
Minimum concentration of the analyte in plasma (Cmin)
时间窗: up to day 40
Area under the plasma concentration time curve over the dosing interval (AUCτ)
时间窗: up to day 40
次要结局
- Number of patients with abnormal changes in laboratory parameters(up to day 40)
- Number of patients with clinically significant changes in vital signs(up to day 39)
- Time of Cmax (Tmax)(up to day 40)
- Number of patients with adverse events(up to 40 days)
- Oral clearance (Cl/F)(up to day 40)
研究者
相似试验
已完成
4 期
Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ PatientsHIV InfectionsNCT02184078Boehringer Ingelheim19
已完成
4 期
A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic FunctionsHIV InfectionsHepatic InsufficiencyNCT00144248Boehringer Ingelheim51
已完成
1 期
An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.HIV InfectionsNCT00002194Boehringer Ingelheim36
已完成
2 期
Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)AidsHiv InfectionsTuberculosisNCT00495326French National Agency for Research on AIDS and Viral Hepatitis570
已完成
3 期
A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their InfantsPregnancyHIV InfectionsNCT00001135National Institute of Allergy and Infectious Diseases (NIAID)2,009